The global protein drugs market should reach $394.2 billion by 2026 from $265.0 billion in 2021 at a compound annual growth rate (CAGR) of 8.3% for the forecast period of 2021 to 2026.
The monoclonal antibodies segment of the global protein drugs market is expected to grow from $126.7 billion in 2021 to $208.6 billion in 2026 at a CAGR of 10.5% for the forecast period of 2021 to 2026.
The vaccines segment of the global protein drugs market is expected to grow from $35.4 billion in 2021 to $50.4 billion in 2026 at a CAGR of 7.3% for the forecast period of 2021 to 2026.
Report Scope
This report will focus on protein drugs, classification and manufacturing technologies. The protein drugs market can be classified into peptide hormones, monoclonal antibodies, cytokines, therapeutic enzymes, blood factors, vaccines and peptide antibiotics. This report focuses on six techniques for manufacturing protein therapeutics, including fractionation from natural human/animal sources, microbial fermentation, cell culture, chemical synthesis, transgenics and embryonated eggs. The report focuses on each market and its applications, regulatory environment, latest trends and developments, drivers, restraints and challenges affecting the market.
The report covers company profiles for all the major companies and also company share analysis. This report also covers market projections to 2026 and relevant patent analysis. By geography, the market has been segmented into the United States, Europe and emerging markets. Emerging markets include India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand. For market estimates, data has been provided for the year 2019, 2020 (as base year) and forecast through 2026.
The Report Includes
- 37 data tables and 28 additional tables
- An overview of the global markets and manufacturing technologies for protein drugs
- Estimation of the market size and analyses of global market trends, with data from 2019 to 2020, estimates for 2021 with projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the current and future market potential and quantification of protein drugs market based on type, manufacturing process and region
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- A detailed description of protein drugs, their classification and six main manufacturing technologies and information on recombinant deoxyribonucleic acid (rDNA) technology
- Information on advancements in manufacturing technologies, new product launches of the industry and discussion on the effect of biosimilars entry to the protein drugs market
- Detailed analysis of the regulatory framework and policies and technological changes within the industry
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
- Comprehensive company profiles of the leading players of the industry, including AbbVie Inc., Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer Inc. and Sanofi S.A.
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- What's New in This Update?
- Scope of Report
- Information Sources
- Research Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Therapeutic Proteins: Overview
- History
- Pharmacological Classification of Therapeutic Proteins
- Protein Therapeutics with Enzymatic or Regulatory Activity
- Protein Therapeutics with Special Targeting Activity
- Protein Vaccines
- Molecular Classification of Therapeutic Proteins
- Cytokines
- Monoclonal Antibodies
- Blood Products
- Peptide Antibiotics
- Vaccines
- Enzymes
- Peptide Hormones
- Manufacturing Technologies
- Fractionation/Extraction from Natural Sources (Human/Animal)
- Microbial Fermentation and Bioreactors
- Transgenics
- Mammalian Cell Culture
Chapter 4 Regulatory Aspects
- Monoclonal Antibodies
- Therapeutic Enzymes
- Cytokines
- Peptide Hormones
- Vaccines
- Blood Products
- Peptide Antibiotics
- Recalls and Safety Alerts
Chapter 5 New Developments
- Monoclonal Antibodies
- Vaccines
- Cytokines
- Peptide Hormones
- Therapeutic Enzymes
- Blood Products
- Peptide Antibiotics
Chapter 6 Market Analysis of Protein Drugs by Type
- Global Market for Protein Drugs by Type
- Market Share
- Monoclonal Antibodies
- Peptide Hormones
- Vaccines
- Blood Factors
- Cytokines
- Therapeutic Enzymes
- Peptide Antibiotics
Chapter 7 Market Analysis of Protein Drugs by Region
- Global Market for Protein Drugs by Region
- Market Share
- Regional Markets for Monoclonal Antibodies
- Regional Markets for Peptide Hormones
- Regional Markets for Vaccines
- Regional Markets for Blood Factors
- Regional Markets for Cytokines
- Regional Markets for Therapeutic Enzymes
- Regional Markets for Peptide Antibiotics
Chapter 8 Market Analysis of Protein Drugs by Manufacturing Process
- Global Market for Protein Drugs by Manufacturing Process
- Market Share
- Monoclonal Antibodies
- Peptide Hormones
- Vaccines
- Blood Factors
- Cytokines
- Therapeutic Enzymes
- Peptide Antibiotics
Chapter 9 Competitive Landscape
- Mergers and Acquisitions
- Monoclonal Antibodies
- Market Share
- Peptide Hormones
- Market Share
- Vaccines
- Market Share
- Blood Factors
- Market Share
- Cytokines
- Market Share
- Therapeutic Enzymes
- Market Share
- Peptide Antibiotics
- Market Share
Chapter 10 Market Dynamics
- Market Drivers
- Prevalence of Chronic Diseases
- Growing Aging Population
- Advancements in Manufacturing Technologies
- New Product Launches
- Licensing and Collaboration Agreements
- Market Challenges
- Price Controls
- Regulatory Pressures
- Entry of Biosimilars
- Impact of COVID-19 on Protein Drugs Market
Chapter 11 Patent Analysis
Chapter 12 Company Profiles
- Abbvie Inc.
- Alexion Pharmaceuticals
- Amgen Inc.
- Apotex Inc.
- Bayer Pharmaceuticals
- Biogen
- Biomarin Pharmaceutical Inc.
- Bristol-Myers Squibb
- Biotest
- CSL Ltd.
- Eli Lilly
- F. Hoffmann-La Roche Ag
- Fresenius Kabi
- Glaxosmithkline
- Grifols S.A.
- Johnson & Johnson
- Merck & Co., Inc.
- Merck Kgaa
- Novo Nordisk Ag
- Novartis Ag
- Octapharma Ag
- Pfizer Inc.
- Sandoz
- Sanofi S.A.
- Seagen
- Takeda Pharmaceutical Co., Ltd.
- UCB Co.
List of Tables
Summary Table: Global Market for Protein Drugs, by Type, Through 2026
Table 1: Evolution of Therapeutic Proteins
Table 2: Protein Drugs Made by Fractionation
Table 3: Therapeutic Drugs Produced by Microbial Fermentation
Table 4: Protein Drugs Produced by Transgenic Animals, Plants and Microorganisms
Table 5: Protein Drugs Made by Cell Culture
Table 6: Newly Approved Monoclonal Antibodies, 2019-May 2021
Table 7: Newly Approved Peptide Hormones, 2019-May 2021
Table 8: Newly Approved Vaccines, 2019-May 2021
Table 9: Newly Approved Blood Products, 2019-May 2021
Table 10: Newly Approved Peptide Antibiotics, 2019-May 2021
Table 11: Recalls and Safety Alerts, 2019-May 2021
Table 12: Pipeline Products: Monoclonal Antibodies
Table 13: Pipeline Products: Vaccines
Table 14: Pipeline Products: Cytokines
Table 15: Pipeline Products: Peptide Hormones
Table 16: Pipeline Products: Therapeutic Enzymes
Table 17: Pipeline Products: Peptide Hormones
Table 18: Pipeline Products: Peptide Antibiotics
Table 19: Global Market for Protein Drugs, Through 2026
Table 20: Global Market for Protein Drugs, by Type, Through 2026
Table 21: Global Market for Monoclonal Antibodies, by Type, Through 2026
Table 22: Global Market for Peptide Hormones, by Type, Through 2026
Table 23: Global Market for Vaccines, by Type, Through 2026
Table 24: Global Market for Blood Factors, by Type, Through 2026
Table 25: Global Market for Cytokines, by Type, Through 2026
Table 26: Global Market for Therapeutic Enzymes, by Type, Through 2026
Table 27: Global Market for Peptide Antibiotics, by Type, Through 2026
Table 28: Global Market for Protein Drugs, by Region, Through 2026
Table 29: Global Market for Monoclonal Antibodies, by Region, Through 2026
Table 30: Global Market for Peptide Hormones, by Region, Through 2026
Table 31: Global Market for Vaccines, by Region, Through 2026
Table 32: Global Market for Blood Factors, by Region, Through 2026
Table 33: Global Market for Cytokines, by Region, Through 2026
Table 34: Global Market for Therapeutic Enzymes, by Region, Through 2026
Table 35: Global Market for Peptide Antibiotics, by Region, Through 2026
Table 36: Global Market for Protein Drugs, by Manufacturing Process, Through 2026
Table 37: Global Market for Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 38: Global Market for Peptide Hormones, by Manufacturing Process, Through 2026
Table 39: Global Market for Vaccines, by Manufacturing Process, Through 2026
Table 40: Global Market for Blood Factors, by Manufacturing Process, Through 2026
Table 41: Global Market for Cytokines, by Manufacturing Process, Through 2026
Table 42: Global Market for Therapeutic Enzymes, by Manufacturing Process, Through 2026
Table 43: Global Market for Peptide Antibiotics, by Manufacturing Process, Through 2026
Table 44: Mergers and Acquisitions: Pharmaceutical Companies
Table 45: AbbVie Inc.: Business Segments
Table 46: AbbVie Inc.: Financial Performance, 2018-2020
Table 47: Amgen: Financial Performance, 2018-2020
Table 48: Bristol-Myers Squibb: Financial Performance, 2018-2020
Table 49: Eli Lilly: Business Segments
Table 50: Eli Lilly: Financial Performance, 2018-2020
Table 51: F. Hoffmann-La Roche: Business Segments
Table 52: F. Hoffmann-La Roche: Financial Performance, 2018-2020
Table 53: GlaxoSmithKline: Product Segments
Table 54: GlaxoSmithKline: Financial Performance, 2018-2020
Table 55: Johnson & Johnson: Business Segments
Table 56: Johnson & Johnson: Financial Performance, 2018-2020
Table 57: Merck & Co., Inc.: Business Segments
Table 58: Merck & Co., Inc.: Financial Performance, 2018-2020
Table 59: Novo Nordisk: Business Segments
Table 60: Novo Nordisk: Financial Performance, 2018-2020
Table 61: Pfizer: Business Segments
Table 62: Pfizer: Financial Performance, 2018-2020
Table 63: Sanofi: Business Segments
Table 64: Sanofi: Financial Performance, 2018-2020
List of Figures
Summary Figure: Global Market for Protein Drugs, by Type, 2019-2026
Figure 1: Global Market for Protein Drugs, 2019-2026
Figure 2: Global Market Shares of Protein Drugs, by Type, 2020
Figure 3: Global Market for Monoclonal Antibodies, by Type, 2019-2026
Figure 4: Global Market for Peptide Hormones, by Type, 2019-2026
Figure 5: Global Market for Vaccines, by Type, 2019-2026
Figure 6: Global Market for Blood Factors, by Type, 2019-2026
Figure 7: Global Market for Cytokines, by Type, 2019-2026
Figure 8: Global Market for Therapeutic Enzymes, by Type, 2019-2026
Figure 9: Global Market for Peptide Antibiotics, by Type, 2019-2026
Figure 10: Global Market for Protein Drugs, by Region, 2019-2026
Figure 11: Global Market Shares of Protein Drugs, by Region, 2020
Figure 12: Global Market for Monoclonal Antibodies, by Region, 2019-2026
Figure 13: Global Market for Peptide Hormones, by Region, 2019-2026
Figure 14: Global Market for Vaccines, by Region, 2019-2026
Figure 15: Global Market for Blood Factors, by Region, 2019-2026
Figure 16: Global Market for Cytokines, by Region, 2019-2026
Figure 17: Global Market for Therapeutic Enzymes, by Region, 2019-2026
Figure 18: Global Market for Peptide Antibiotics, by Region, 2019-2026
Figure 19: Global Market for Protein Drugs, by Manufacturing Process, 2019-2026
Figure 20: Global Market Shares of Protein Drugs, by Manufacturing Process, 2020
Figure 21: Global Market for Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 22: Global Market for Peptide Hormones, by Manufacturing Process, 2019-2026
Figure 23: Global Market for Vaccines, by Manufacturing Process, 2019-2026
Figure 24: Global Market for Blood Factors, by Manufacturing Process, 2019-2026
Figure 25: Global Market for Cytokines, by Manufacturing Process, 2019-2026
Figure 26: Global Market for Therapeutic Enzymes, by Manufacturing Process, 2019-2026
Figure 27: Global Market for Peptide Antibiotics, by Manufacturing Process, 2019-2026
Figure 28: Global Manufacturer/Supplier Market Shares of Monoclonal Antibodies, 2020
Figure 29: Global Manufacturer/Supplier Market Shares of Peptide Hormones, 2020
Figure 30: Global Manufacturer/Supplier Market Shares of Vaccines, 2020
Figure 31: Global Manufacturer/Supplier Market Shares of Blood Factors, 2020
Figure 32: Global Manufacturer/Suppliers Market Shares of Cytokines, 2020
Figure 33: Global Manufacturer/Supplier Market Shares of Therapeutic Enzymes, 2020
Figure 34: Global Manufacturer/Supplier Market Shares of Peptide Antibiotics, 2020
Figure 35: AbbVie Inc.: Net Revenue Share, by Business Segment, 2020
Figure 36: AbbVie Inc.: Net Revenue Share, by Region, 2020
Figure 37: Amgen: Total Sales Share, by Product Segment, 2020
Figure 38: Amgen: Total Revenue Share, by Region, 2020
Figure 39: Bristol Myers Squibb: Total Sales Share, by Product Segment, 2020
Figure 40: Company website/financial filings
Figure 41: Eli Lilly: Total Sales Share, by Product Segment, 2020
Figure 42: Eli Lilly: Total Revenue Share, by Region, 2020
Figure 43: F. Hoffmann-La Roche: Total Sales Share, by Product Segment, 2020
Figure 44: F. Hoffmann-La Roche: Total Revenue Share, by Region, 2020
Figure 45: GlaxoSmithKline: Total Sales Share, by Product Segment, 2020
Figure 46: GlaxoSmithKline: Total Revenue Share, by Region, 2020
Figure 47: Johnson & Johnson: Total Sales Share, by Business Segment, 2020
Figure 48: Johnson & Johnson: Total Revenue Share, by Region, 2020
Figure 49: Merck & Co., Inc.: Revenue Share, by Business Segment, 2020
Figure 50: Merck & Co., Inc.: Revenue Share, by Region, 2020
Figure 51: Novo Nordisk: Revenue Share, by Business Segment, 2020
Figure 52: Novo Nordisk: Revenue Share, by Region, 2020
Figure 53: Pfizer: Revenue Share, by Business Segment, 2020
Figure 54: Pfizer: Revenue Share, by Region, 2020
Figure 55: Sanofi: Net Sales Share, by Business Segment, 2020
Figure 56: Sanofi: Net Sales Share, by Region, 2020
Samples
LOADING...
Executive Summary
Proteins, an important class of regulatory molecules, are the building blocks of the body. Protein therapeutics has become an important segment of the healthcare industry. Genetic engineering technology makes it possible to produce these protein molecules with modified features. Due to high specificity and low immunogenicity, protein therapeutics is widely used to treat various life-threatening diseases such as cancer, diabetes and multiple sclerosis.
Increasing R&D, sedentary lifestyles, increasing incidence of various diseases, and the increasing population of baby boomers drive this market.
Monoclonal antibodies are the largest segment in terms of revenue. The use of monoclonal antibodies has increased due to the increase in various chronic diseases. However, the market is facing competition from the entry of follow-on biologics. Insulin analogs, which are more efficient than recombinant insulin, are a contributing factor for the growth of the market. Vaccines are another growth segment in the biopharmaceutical industry. The COVID-19 pandemichas led to increasing public awareness toward vaccination. Government efforts to eradicate viral and bacterial infections are driving factors for the vaccine market. Improved manufacturing technologies have also fueled the vaccine market. Some key players in the protein drug market include F. Hoffmann-LaRoche Ltd., AbbVie Inc., Amgen Inc., Biogen Inc., Sanofi S.A., Novo Nordisk, GlaxoSmithKline, Merck & Co. and more.
The U.S. leads the protein therapeutics market. Follow-on-biologics and price pressures are the major threats for the market. A rapid increase in medical technologies, improved diagnosis of disease, and the expansion of healthcare in emerging markets are expected to positively impact the protein therapeutics market.
The global market was further segmented by manufacturing processes; protein therapeutics made through cell culture had the biggest share.
Companies Mentioned
- Abbvie Inc.
- Alexion Pharmaceuticals
- Amgen Inc.
- Apotex Inc.
- Bayer Pharmaceuticals
- Biogen
- Biomarin Pharmaceutical Inc.
- Biotest
- Bristol-Myers Squibb
- CSL Ltd.
- Eli Lilly
- F. Hoffmann-La Roche Ag
- Fresenius Kabi
- Glaxosmithkline
- Grifols S.A.
- Johnson & Johnson
- Merck & Co., Inc.
- Merck Kgaa
- Novartis Ag
- Novo Nordisk Ag
- Octapharma Ag
- Pfizer Inc.
- Sandoz
- Sanofi S.A.
- Seagen
- Takeda Pharmaceutical Co., Ltd.
- UCB Co.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 159 |
| Published | August 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 265 Billion |
| Forecasted Market Value ( USD | $ 394.2 Billion |
| Compound Annual Growth Rate | 8.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
